What's Happening?
Verastem Oncology has decided to deprioritize its investigational drug combination for metastatic pancreatic cancer following a Phase 1b/2a study. The study showed a treatment response in over half of the patients, but the results were overshadowed by
the performance of Revolution Medicines' daraxonrasib, which nearly doubled overall survival compared to chemotherapy. Verastem's combination, which includes the MEK kinase inhibitor Avmapki (avutometinib) and the FAK inhibitor Fakzynja (defactinib), showed an overall survival rate of 86% and an objective response rate of 52%. Despite these results, Verastem has chosen to focus on its investigational KRAS G12D inhibitor, VS-7375, which is in mid-stage development for KRAS G12D-mutated solid tumors such as colorectal cancer and non-small cell lung cancer.
Why It's Important?
The decision by Verastem to shift its focus highlights the competitive nature of the oncology drug development landscape, particularly in the field of pancreatic cancer treatment. Revolution Medicines' success with daraxonrasib sets a high benchmark, influencing Verastem's strategic direction. This move could impact the company's market position and resource allocation, as it pivots towards developing treatments for KRAS G12D mutations, which are prevalent in various cancers. The shift also underscores the challenges smaller biotech firms face in competing with more established players with successful drug candidates.
What's Next?
Verastem plans to continue evaluating the potential of avutometinib plus defactinib in metastatic pancreatic cancer, exploring future development opportunities and potential strategic collaborations. The company will now concentrate its efforts on advancing VS-7375, aiming to address the unmet needs in treating KRAS G12D-mutated cancers. This strategic pivot may involve seeking partnerships or collaborations to enhance the development and commercialization of their pipeline products.
